Login
Register
RSS
Corporate
Events
Gene
Indepth
News
Publish
Report Store
Resources
VideoBiotechnology and Pharmaceutical News
All Articles ordered by score descending using keyword "Datamonitor_7"Showing results 0 - 15 of 152
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL | Today | Past Week | Past Month | Past Year
- China and India pharma sectors see M&A spikeAustralian Life Scientist | A report by analyst group Datamonitor has identified China and Indias pharmaceutical industries as the ones to watch following a flurry of M&A activity over the last three years. Of the 400 transactions analysed by Datamonitor in the region between 2007 and this year, 32 percent involved healthcare and pharmaceutical companies from China, including Hong Kong, with India...
- China and India pharma companies driving M&A activity in AsiaAustralian Life Scientist | A report by analyst group Datamonitor has identified China and Indias pharmaceutical industries as the ones to watch following a flurry of M&A activity over the last three years. Of the 400 transactions analysed by Datamonitor in the region between 2007 and this year, 32 percent involved healthcare and pharmaceutical companies from China, including Hong Kong, with India...
- Asia Drug Company Mergers, Buyouts to Increase in 2010, Datamonitor SaysCafepharma | Mergers and acquisitions within the pharmaceutical industry in Asia and the Pacific will increase this year, provided the world economy remains stable and governments in the regions developing nations continue to push ahead with ongoing health-care reforms and regulatory policy reviews, Datamonitor Group said. The regions offer advantages to companies pursuing growth prospects through...
- Monsanto acquires 19.9% stake in InterGrain Deal In BriefQuote.com Australia | (Datamonitor Financial Deals Tracker via COMTEX News Network) -- Monsanto Company, a US-based provider of technology-based solutions and agricultural products, has acquired a 19.9 % stake in Intergrain Pty., Ltd., an Australia-based crop breeding company. Simultaneously, Monsanto and Intergrain have entered into technology collaboration for wheat technology. Deal Participants...
- Biodel announces name change for insulin drugTMC Net | (Datamonitor via COMTEX) -- Biodel, a specialty biopharmaceutical company, has a...
- Datamonitor: GlaxoSmithKline/Valeant - boost for Potiga ahead of final FDA reviewPRLog | - FDA approval now seems likely and Datamonitor forecasts peak sales of almost $300m in 2017, prolonging GlaxoSmithKline's share of the $3 billion epilepsy market. GlaxoSmithKline and Valeant's novel antiepileptic drug Potiga (ezogabine) received a boost when an FDA advisory committee voted unanimously that the drug was effective as an adjunctive treatment in patients with partial onset se...
- New Market Research Report: Octapharma AG - SWOT AnalysisPR inside | Recently published research from Datamonitor, "Octapharma AG - SWOT Analysis", is now available at Fast Market Research Datamonitor's Octapharma AG - SWOT Analysis company profile is the essential source for top-level company data and information. Octapharma AG - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analy...
- New Market Reports by Datamonitor Published at MarketPublishers.comLONDON, July 6, 2010 /PRNewswire/ -- Market Publishers Ltd informs that new in-demand market
reports by Datamonitor (http://marketpublishers.com/members/datamonitor/
info.html) are available in its catalogue.
(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser...Published: 00:00 EST Tuesday the 6th of July 2010 | Press Release by Newswire
Views - General: 9 / Professonals: 0 / Researchers: 0 / Total: 9 / Stats - M&As on the rise in APAC healthcare markets: DatamonitorBio Spectrum Asia | The sheer size and purchasing power of patient populations in emerging Asia Pacific (APAC) healthcare markets, combined with improving regulatory and business environments, is attracting pharma companies from far and wide, according to the latest analysis by Datamonitor. The latest report on 'Pharmaceutical M&A in the Asia Pacific Region' reveals that emerging regional gian...
- Now Available: Commercial Insight: Antihormonal Cancer TherapiesPR inside | Fast Market Research recommends 'Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion' from Datamonitor, now available Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potentia...
- Strides Arcolab receives FDA approval for vitamin D capsulesPharmacy Choice | (Datamonitor via COMTEX) Strides Arcolab, an Indian pharmaceutical company, has received FDA approval for Ergocalciferol capsules USP 1.25mg. Ergocalciferol is a synthetic calcium regulator for oral administration. Each capsule contains vitamin D (Ergocalciferol) 1.25mg equivalent to 50,000 USP units of vitamin D and will be available in bottles of 50 & 100s, the company said. Th...
- Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face ofPR inside | New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries ...
- New Pharmaceuticals research report from Datamonitor is now availablePRLog | - In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019. Scope * Analysis...
- Amneal wins FDA approval for Spironolactone HCl tabletsPharmacy Choice | (Datamonitor via COMTEX) Amneal Pharmaceuticals has received US FDA approval to manufacture Spironolactone HCl tablets in 25mg, 50mg and 100mg strengths. The Amneal generic is an AB-rated, therapeutically equivalent alternative to Aldactone. Amneal began shipping Spironolactone HCl in 100 and 500 count sizes. The 25mg strength can also be ordered in 1000 count size. This product ...
- New Market Research Report: Biotechnology in ChinaPR inside | Fast Market Research recommends "Biotechnology in China" from Datamonitor, now available Datamonitor's Biotechnology in China industry profile is an essential resource for top-level data and analysis covering the Biotechnology industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies an...